Identification of Novel MicroRNAs as Promising Therapeutics for SARS-CoV-2 by Regulating the EGFR-ADAM17 Axis: An In Silico Analysis

Debasmita Mukhopadhyay; Nour AlSawaftah; Ghaleb A Husseini

doi:10.1021/acsptsci.0c00199

Identification of Novel MicroRNAs as Promising Therapeutics for SARS-CoV-2 by Regulating the EGFR-ADAM17 Axis: An In Silico Analysis

ACS Pharmacol Transl Sci. 2020 Dec 9;4(1):396-399. doi: 10.1021/acsptsci.0c00199. eCollection 2021 Feb 12.

Authors

Debasmita Mukhopadhyay¹, Nour AlSawaftah¹, Ghaleb A Husseini¹

Affiliation

¹ Chemical Engineering Department, American University of Sharjah, Sharjah, United Arab Emirates.

Abstract

Cancer patients contracting SARS-CoV-2 encounter additional challenges due to inflammatory bursts and lymphopenia, which may aggravate breast cancer prognosis. In this in silico analysis, we identified the potential of miRNAs as new therapeutic targets to treat breast cancer patients infected with COVID-19 via the regulation of ADAM17 and EGFR expression microRNAs.